Stay updated with breaking news from Thyroid Associated. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
-- Updated indication language reinforces the importance of unrestricted access for patients across full spectrum of Thyroid Eye Disease -- ... | April 14, 2023
-- At Week 24, patients treated with TEPEZZA achieved a 2.41 mm reduction in proptosis from baseline compared with 0.92 mm for those receiving placebo -- -- 62% of patients treated with TEPEZZA had... | April 10, 2023
-- Data presented at the North American Neuro-Ophthalmology Society (NANOS) Annual Meeting on March 11-16 in Orlando -- Horizon Therapeutics plc (Nasdaq: HZNP) today announced results of an analysis
Horizon Therapeutics plc Announces Completion of Enrollment of Phase 3 Clinical Trial (OPTIC-J) in Japan Evaluating TEPEZZA® (teprotumumab-trbw) for the Treatment of Active Thyroid Eye Disease (TED) - read this article along with other careers information, tips and advice on BioSpace
-- Analysis presented at American Thyroid Association Annual Meeting (ATA 2022) shows during a two-year period, 4.9% of patients who completed a full course of TEPEZZA were later prescribed a second